Omeros (NASDAQ:OMER) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a research report released on Saturday.

A number of other brokerages also recently issued reports on OMER. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research note on Friday. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. WBB Securities restated a “strong-buy” rating and set a $45.00 price objective on shares of Omeros in a research report on Wednesday, October 15th. HC Wainwright lifted their target price on shares of Omeros from $9.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Omeros has an average rating of “Moderate Buy” and a consensus price target of $33.67.

Omeros Price Performance

OMER opened at $9.08 on Friday. The firm has a market capitalization of $617.95 million, a price-to-earnings ratio of -4.30 and a beta of 2.40. The company’s 50 day simple moving average is $5.88 and its two-hundred day simple moving average is $4.57. Omeros has a 1-year low of $2.95 and a 1-year high of $13.60.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.39. On average, equities analysts anticipate that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omeros

A number of institutional investors have recently made changes to their positions in OMER. Deutsche Bank AG lifted its holdings in shares of Omeros by 4.9% in the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company’s stock worth $345,000 after acquiring an additional 1,973 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Omeros by 11.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 29,097 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 2,941 shares during the period. Harbour Investments Inc. raised its position in Omeros by 51.9% in the first quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,149 shares during the period. Bank of New York Mellon Corp lifted its stake in Omeros by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company’s stock worth $1,242,000 after purchasing an additional 3,321 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 5,677 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.